Independent minds. Global perspective. A publication for the builders
Biotechnology / San Francisco

Parsa Modareszadeh.

Co-founder
Velorum Therapeutics

Parsa Modareszadeh co-founded Velorum Therapeutics, which researches medicines based on the biology of heme. The public biography identifies a focus on drug development. The company's public launch describes investigating cancer metabolism and developing compounds intended to interfere with a resource that some tumors use.

Public-source researchLast checked 1 source ↘
THE STORY, IN CONTEXT

Parsa Modareszadeh and the story of Velorum Therapeutics.

Velorum's public account presents heme availability as a possible route for targeting tumor metabolism. Its launch describes preclinical work and future clinical ambitions, connecting a biological hypothesis with drug-development plans. Those statements concern an investigational program rather than an approved treatment. The supplied evidence establishes the research focus without independently confirming selectivity, safety, clinical effectiveness, or the expectation that an experimental medicine will work in people.

FROM THE PUBLIC RECORD

Public advice & further reading.

No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.

Suggest a first-person interview or essay ↗
EVIDENCE IN PLAIN SIGHT

Sources & attribution.

  1. 01
    Velorum Therapeutics — Y Combinator company and active founder profile

    Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.

    www.ycombinator.com
About this profile

Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.

Request a correction or update ↗
KEEP EXPLORING

More builders in Biotechnology.

Explore the sector ↗